1. Zyuzin MV, Díez P, Goldsmith M, Carregal-Romero S, Teodosio C, Rejman J, Feliu N, Escudero A, Almendral MJ, Linne U, Peer D, Fuentes M, Parak WJ (2017). Comprehensive and Systematic Analysis of the Immunocompatibility of Polyelectrolyte Capsules. Bioconjug ChemPDF
  2. Soffer-Tsur N., Peer D., Dvir T (2016) ECM-based macroporous sponges release essential factors to support the growth of hematopoietic cells. Journal of Controlled ReleasePDF
  3. Kedmi R, Peer D. (2016) Zooming in on selectins in cancer. Sci. Transl. Med.  29;8(345):345. PDF
  4. S. Weinstein, I.A. Toker, R. Emmanuel, S. Ramishetti, I. Hazan-Halevy, D. Rosenblum, M. Goldsmith, A. Abrahamc, O. Benjamini, O. Bairey, P. Raanani, A. Nagler, J. Liebermane,and D. Peer. (2016) Harnessing RNAi based-nanomedicines for therapeutic gene silencing in B cell malignancies.  Proc. Natl. Acad. Sci. USA 113(1) E16-E22. PDF
  5. Dearling, J., Daka, A., Veiga, N., Peer, D., and Packard A. (2016) ImmunoPET of colitis: defining target cell populations and
    optimizing pharmacokinetics. Inflammatory Bowel Diseases 22(3):529-538. PDF
  6. Ben-Arye T., Park S., Shemesh J., Peer D., Levenberg S. and Yossifon G. (2015) Dielectrophoretic characterization of cells in a stationary nanoliter droplet array with generated chemical gradients. Biomed Microdevices 17: 91. PDF
  7. Ramishetti S.*, Kedmi R.*, Goldsmith M., Leonard F., Speague AG., Godin B., Gozin M., Cullis P., Dykxhoorn DM., and Peer D (2015) Systemic Gene Silencing in Primary T lymphocytes using Targeted Lipid Nanoparticles. ACS Nano 9(7):6706-6716 *denotes equal contribution. PDF
  8. Yang D., Zeng T., Yang Y., Wang X., Hu J., Song Y., Chen L., Peer D., Wang X., and Bai C (2015) Specific serum chemokines network correlates with Serum chemokine network correlates with chemotherapy in non-small cell lung cancer. Cancer Letters. 365(1), 57-67. PDF
  9. Hazan-Halevy I.*, Rosenblum D.*,Weinstein S.,Bairey O., Raanani P. and Peer D (2015) Cell-specific uptake of mantle cell lymphoma-derived exosomes by malignant and non-malignant B-lymphocytes. Cancer Letters. 364(1), 59-69. *denotes equal contribution. PDF
  10. Nadejda S., Kaplan Zeevi M., Weinstein S., Peer D. and Herskovits AA (2015). The human P-glycoprotein Transporter enhances Type I Interferon Response to L. monocytogenes Infection. Infection and Immunity. 83(6), 2358-2368. PDF
  11. Jacoby G.*, Cohen K.*, Tamon I., Peer D *. and Back-Barkai R* (2015) Metastability in lipid based particles exhibits temporally deterministic and controllable behavior. Scientific Reports 5, 9481, 1-7.*denotes equal contribution. PDF
  12. Cao Y. Gao M., Chen C., Fan A., Zhang J., Kong D., Wang Z., Peer, D. and Zhao, Y (2015) Triggered-release polymeric conjugate micelles for on-demand intracellular drug delivery. Nanotechnology 26, 1-9. PDF
  13. Cohen ZR*, Ramishetti S*, Peshes-Yaloz N*, Goldsmith M, Wohl A, Zibly Z, and Peer D (2015). Localized RNAi Therapeutics of Chemo-Resistant Grade IV Glioma using Hyaluronan-Grafted Lipid-Based Nanoparticles. ACS Nano. 9(2), 1581-1591.*denotes equal contribution,  PDF
  14. Perevedentseva E., Peer D., Uvarov V., Zousman B. and Levinson O (2015) Nanodiamonds of Laser Synthesis for Biomedical Applications. J. Nanosci. Nanotech. 15, 1045-1052.
  15. Drinberg V., Bitcover R., Rajchenbach W. and Peer D (2014) Modulating Cancer Multidrug Resistance by Sertraline in Combination with a Nanomedicine. Cancer Letters 354, 290-298. PDF
  16. Soffer-Tsur N, Shevach M, Shapira A, Peer D, Dvir T (2014) Optimizing the biofabrication process of omentum-based scaffolds for engineering autologous tissues. Biofabrication 6PDF
  17. Amar-Lewis E., Azagury A., Goldbart R., Traitel T., Prestwood J., Landesman-Milo D., Peer D., Kost J. (2014) Quaternized Starch Based Carrier for siRNA Delivery: from Cellular Uptake to Gene Silencing. Journal of Controlled Release 185, 118-120. PDF
  18. Cohen K, Emmanuel R., Kisin-Finfer E., Shabat D., and Peer, D. (2014) Modulation of Drug Resistance in Ovarian Adenocarcinoma using Chemotherapy Entrapped in Hyaluronan-Grafted Nanoparticle Clusters. ACS Nano 8(3), 2185-2193. PDF
  19. Mizrahy S., Goldsmith M., Leviatan-Ben-Arye S., Kisin-Finfer E., Redy O., Srinivasan S. , Shabat D., Godin B., and Peer D. (2014) Tumor targeting profiling of Hyaluronan-coated lipid based-nanoparticles. Nanoscale 6, 3742-3752. PDF
  20. Amram S., Ganoth A., Tichon O, Peer D., Nachliel E. , Gutman M., and Tsfadia Y (2014) Structural characterization of the drug translocation path of MRP1/ABCC1. Israeli Journal of Chemistry 54, 1382-1393. PDF
  21. Peer D. and Howard KA (2014). RNA Interference-based Therapeutics and Diagnostics. Drug Delivery and Translation Research 4, 1-2. PDF
  22. Wang X., Peer D., and Petersen B (2013) Molecular and Cellular Therapies: New Challenges and Opportunities. Molecular and Cellular Therapies 1, 1-4.  PDF
  23. Dahan L., Huang L., Kedmi R., Behlke MA, and Peer D (2013) SNP detection in mRNA in living cells using allele specific FRET probes. PLoS ONE 8(9) e72389. PDF
  24. Dvash R., Khatchatouriants A, Solmesky LJ, Wibroe PP., Weil M., Moghimi SM., and Peer D (2013) Structural profiling and biological performance of phospholipid-hyaluronan functionalized single-walled carbon nanotubes. Journal of Controlled Released 170, 295-305. PDF
  25. Landesman-Milo D., and Peer D (2013) Toxicity profiling of several common RNAi-based nanomedicines: A comparative study. Drug Delivery and Translational Research 334, 221-227. PDF 
  26. Emmanuel R., Weinstein S., Landesman-Milo D. and Peer D (2013) eiF3c: A potential therapeutic target for cancer. Cancer Letters 336, 158-166. PDF
  27. Elinav E, Peer D. (2013) Harnessing Nanomedicine for Mucosal Theranostics-A Silver Bullet at Last? ACS Nano. 7(4), 2883-2890. PDF
  28. Landesman-Milo D, Goldsmith M, Arie SL, Witenberg B, Brown E,  Leibovitch S, Azriel S, Tabak S, Morad V, Peer D.(2013) Hyaluronan grafted lipid-based nanoparticles as RNAi carriers for cancer cells. Cancer Letters 334, 221-227. PDF
  29. Weinstein S, Emmanuel R, Jacobi AM, Abraham A, Behlke MA, Sprague AG, Novobrantseva TI, Nagler A, Peer D. (2012) RNA inhibition highlights cyclin d1 as a potential therapeutic target for mantle cell lymphoma. PLoS One 7(8):e43343. PDF
  30. Moyano D., Goldsmith M., Solfiell D., Landesman-Milo D., Miranda O., Peer D.* and Rotello VM* (2012). Hydrophobicity Dictates Immune response. Journal of American Chemical Society 134(9), 3965-3967. *denotes equal contribution. PDF
  31. Ben-Arie N, Kedmi R. and Peer D (2012). Integrin-Targeted Nanoparticles for siRNA Delivery. Methods in Molecular.757, 497-507. PDF
  32. Srinivasan C, Peer D, and Shimaoka M (2012). Integrin Targeted Stabilized Nanoparticles for an  efficient Delivery of siRNAs in vitro and in vivo. Methods in Molecular Biology 820, 105-116. PDF
  33. Breiner-Goldstein E, Evron Z, Frenkel M, Cohen K, Nir Meiron K, Peer D, Roichman Y, Flescher E, and Fridman M (2011) Targeting Anthracycline-resistant Tumor Cells with Synthetic Aloe-emodin Glycosides. ACS Medicinal Chemistry Letters 2, 528-531
  34. Solmesky LJ, Shuman M, Goldsmith M, Weil M, Peer D (2011) Assessing cellular toxicities in fibroblasts upon exposure to lipid-based nanoparticles: a high content analysis approach. Nanotechnology 22(49), 494016. PDF
  35. Moghimi SM, Peer D, Langer R (2011) Reshaping the Future of Nanopharmaceuticals: Ad ludicium. ACS Nano. 5(11), 8454-8458. PDF
  36. Mizrahy S, Raz SR, Hasgaard M, Liu H, Soffer-Tsur N, Cohen K, Dvash R, Landsman-Milo D, Bremer MG, Moghimi SM, Peer D. (2011) Hyaluronan-coated nanoparticles: The influence of the molecular weight on CD44-hyaluronan interactions and on the immune response. Journal of Controlled Release 156(2), 231-238. PDF
  37. Bachar G, Cohen K, Hod R, Feinmesser R, Mizrachi A, Shpitzer T, Katz O, Peer D. (2011) Hyaluronan-grafted particle clusters loaded with Mitomycin C as selective nanovectors for primary head and neck cancers. Biomaterials 32(21), 4840-4848. PDF
  38. Kim SS, Subramanya S, Peer D, Shimaoka M, Shankar (2011) Antibody-mediated delivery of siRNAs for anti-HIV therapy. Methods Mol. Biol. 721,339-353. PDF
  39. Drug E, Landesman-Milo D, Belgorodsky B, Ermakov N, Frenkel-Pinter M, Fadeev L, Peer D, Gozin M (2011) Enhanced Bioavailability of Polyaromatic Hydrocarbons in the Form of Mucin complexes. Chemical research in toxicology 24(3), 314-320. PDF
  40. Cohen-Kupiec R, Weinstein S, Kantor G, Peer D, Weil M. (2010) IKAP/hELP1 down-regulation in neuroblastoma cells causes enhanced cell adhesion mediated by contactin overexpression. Cell Adh. Migr. 4(4):541-550. PDF
  41. Rivkin I, Cohen K, Koffler J, Melichov D., Peer D*, and Margalit R* (2010) Paclitaxel-clusters coated with hyaluronan as selective tumor-targeted nanovectors. Biomaterials 31, 7106-7114. *denotes equal contribution. PDF
  42. Kedmi R*, Ben-Arie N*, and Peer D (2010). The systemic toxicity of positively charged lipid nanoparticles and the role of Toll-like receptor 4 in immune activation. Biomaterials 31, 6867-6875. *denotes equal contribution. PDF
  43. Dearling JLJ, Voss S, Dunning P, Park EJ, Fahey F, Treves T Solapino S., Shimaoka M, Packard AB, and Peer D (2010) Detection of Intestinal Inflammation by microPET Imaging Using a 64Cu-Labeled Anti-b7 Integrin Antibody. Inflammatory bowel diseases 16(9), 1458-1466. PDF
  44. Kim S-S*, Peer D*, Kumar P*, Subramanya S, Wu H, Asthana D, Habiro K, Yang Y-G, N. Manjunath, Shimaoka M and Shankar P (2010) RNAi-mediated CCR5 silencing by LFA-1-targeted nanoparticles prevents HIV infection in BLT mice. Molecular Therapy 18, 370-376. * denotes equal contribution. PDF
  45. Argov M, Kashi R, Peer D, Margalit R. (2009) Treatment of resistant human colon cancer xenografts by a fluoxetine-doxorubicin combination enhances therapeutic responses comparable to an aggressive bevacizumab regimen. Cancer Letters 274(1), 118-125. PDF
  46. Imai Y, Park EJ, Peer D, Peixoto A, Cheng G, von Andrian UH, Carman CV, Shimaoka M. (2008) Genetic perturbation of the putative cytoplasmic membrane-proximal salt bridge aberrantly activates alpha(4) integrins. Blood 112(13), 5007-5015. PDF
  47. Peer D, Park EJ, Morishita Y, Carman CV, and Shimaoka M (2008) Systemic leukocyte-directed siRNA delivery revealing cyclin D1 as an anti-Inflammation target. Science 319, 627-630. PDF
  48. Peer D, Zhu P, Carman CV, Lieberman J, and Shimaoka M (2007) Selective gene silencing in activated leukocytes by targeting siRNAs to the integrin lymphocyte function- associated antigen-1. Proc. Natl. Acad. Sci. USA, 104, 4095-4100. PDF
  49. Shimaoka M, Kim M, Cohen EH, Yang W, Astrof N, Peer D, Salas A, Ferrand A, Springer TA. (2006) AL-57, a ligand-mimetic antibody to integrin LFA-1, reveals chemokine-induced affinity up-regulation in lymphocytes. Proc. Natl. Acad. Sci. USA 103(38):13991-13996. PDF
  50. Peer D, Dekel Y, Melikhov D, and Margalit R (2004) Fluoxetine inhibits MDR extrusion pumps and enhances therapeutic responses to chemotherapy in syngeneic and human xenograft mouse tumor models. Cancer Research 64, 7562-7569. PDF
  51. Peer D, and Margalit R (2004) Tumor-targeted hyaluronan nano- liposomes increase the antitumor activity of liposomal doxorubicin in syngeneic and human xenografts mouse tumor. Neoplasia 6, 343-353. PDF
  52. Peer D, Margalit R (2004)  Loading mitomycin C inside long circulating hyaluronan targeted nano-liposomes increases its antitumor activity in three mice tumor models. Int. Journal of Cancer 108(5):780-789. PDF
  53. Peer D, Florentin A, Margalit R. (2003) Hyaluronan is a key component in cryoprotection and formulation of targeted unilamellar liposomes. Biochim Biophys. Acta. 1612(1), 76-82. PDF
  54. Peer D, and Margalit R (2000) Physicochemical evaluation of a stability-driven approach to drug entrapment in regular and in surface-modified liposomes. Arch. Biochem. Biophys. 383,185–190. PDF